RAC 2.35% $1.74 race oncology ltd

Ann: Bisantrene Shows Broad Anti-Cancer Activity in Cancer Cells, page-60

  1. 286 Posts.
    lightbulb Created with Sketch. 403
    I recall you mentioning intrathecal administration a couple years ago. Is this something Race have kept in mind while developing the new formulation?

    Maybe this isn't a relevant question now, but possibly interesting. Unless I misunderstood, your comment back then alluded to bisantrene possibly crossing a leaky BBB without being administered intrathecally. Assuming I read that right, are there different levels of severity in a leaky BBB that would change required dosing? Is it a strategy that is employed with other drugs where a framework could be referenced?
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
(20min delay)
Last
$1.74
Change
0.040(2.35%)
Mkt cap ! $296.3M
Open High Low Value Volume
$1.74 $1.82 $1.72 $216.7K 124.1K

Buyers (Bids)

No. Vol. Price($)
1 72 $1.74
 

Sellers (Offers)

Price($) Vol. No.
$1.76 4141 2
View Market Depth
Last trade - 16.10pm 08/07/2024 (20 minute delay) ?
RAC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.